Navigation Links
Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development
Date:4/16/2015

ROCKLAND, Mass., April 16, 2015 /PRNewswire/ -- EMD Serono today announced the US biopharmaceutical business of Merck KGaA, Darmstadt, Germany, appointed Alise Reicin, MD, as Senior Vice President, Head of Global Clinical Development.  Dr. Reicin brings extensive research and early/late clinical development expertise, including experience in Oncology and Immunology. She is an accomplished pharmaceutical executive with strong leadership ability, having served as a Vice President in various capacities across R&D at MSD (Merck Sharp & Dohme) for the last 10 years.

In her role as Head of Global Clinical Development, Reicin will oversee the Clinical Development organization, including the Clinical Development Therapeutic Areas; Evidence Value and Development; Biostatistics; Clinical Operations; and both the Japan and China R&D Hubs.  In this capacity, she will lead the biopharmaceutical business of Merck KGaA, Darmstadt, Germany's portfolio of pipeline programs.

"We are honored to have Alise join us," says Luciano Rossetti, Head of Global Research and Development. "Her impressive experience across diverse areas of clinical research and operations will bring significant value to our organization. She is an accomplished executive whose leadership will serve to significantly advance our clinical development efforts and our strong commitment to enhance our R&D operating model."

Reicin's experience complements the R&D strategy of the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, which focuses on the core therapeutic areas of oncology, immuno-oncology and immunology with several high-priority programs in late development, such as evofosfamide (TH-302) and avelumab (anti-PD-L1), as well as a number of promising early-stage assets.

In the past, Alise served as Vice President, Project and Pipeline Leadership, Oncology Franchise at MSD. In this capacity, she led MSD's PD-1 program and oversaw the initial development and filing activities worldwide, including the first approval in the US.  She also managed program leaders across early and late oncology product development teams. During her tenure at MSD, she held roles of increasing responsibility in R&D, including Vice President and Therapeutic Area Head (Bone, Respiratory, Immunology and Endocrinology); Vice President, Research & Early Development (Bone, Respiratory, Immunology and Endocrinology Franchise Integrator); Vice President, Strategic Realization Office; Vice President and Therapeutic Area Head (Clinical Immunology & Analgesia); and Head of a Transformation Task Force for late clinical development.

Before joining MSD, Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.

Reicin has a degree in biochemistry from Barnard College of Columbia University. She received her Medical Degree from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with MIT (Massachusetts Institute of Technology).

Reicin will report to Luciano Rossetti, Head of Global R&D, and serve as a member of the R&D Executive Leadership Team. Her official start date is on May 11, 2015, and she will be based in Billerica, MA.

EMD Serono

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, is a leading US biopharmaceutical company focused exclusively on specialty care. For more than 40 years, EMD Serono has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.

For more information, please visit www.emdserono.com

Merck KGaA, Darmstadt, Germany

Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

Cory Tromblee
Phone: 781.681.2393

Photo - http://photos.prnewswire.com/prnh/20150415/198968


'/>"/>
SOURCE EMD Serono
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests
2. Emery Oleochemicals Commercialises Production of RSPO Segregated Derivatives, Setting the Sustainability Tone in the Home and Personal Care Industry
3. AstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK In The US
4. DuPont Joins Israel’s Office of the Chief Scientist Global Enterprise R&D Cooperation Framework
5. Brian Cousins Joins Opedix Joint Support Athletic Wear as Vice President of Business Development
6. Leo Gingras Joins Nutraceutical Innovations, LLC Board of Directors
7. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
8. Noted Atherosclerosis Researcher Joins AtheroNova Team
9. Jerry Adams Joins VIC Technology Venture Development Board of Directors
10. Revolutionary new device joins world of smart electronics
11. Jennifer C. Smith, DVM DACLAM, Formerly of Taconic Farms, Inc. Joins the Veterinary Bioscience Institute as the Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... RIDING, Va. (PRWEB) , ... September 01, 2020 ... ... firm for life sciences, biotechnology, and diagnostics companies, has announced the placement of ... . Averill will be responsible for leading all financial operations and implementing key ...
(Date:8/12/2020)... ... 2020 , ... The FSHD Society announced today that it ... Trial Research Network (FSHD CTRN), with consideration of follow-on funding of $300,000 ... research centers in the United States and Europe with expertise in FSHD clinical ...
(Date:8/3/2020)... ... August 03, 2020 , ... ERT, ... President and CEO has been named one of the 100 most inspiring individuals ... PharmaVoice 100 honorees are selected based on how they have inspired their colleagues ...
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, ... that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , ... or two switches in a push-pull configuration; yielding fast fall time for a ...
Breaking Biology Technology:
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced ... will share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional ... Advantage will be live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, ...
(Date:7/1/2020)... , ... July 01, 2020 , ... ... awareness and solutions for glioblastoma—the most common and aggressive adult brain cancer—announced today ... JD, PhD. Senior Fellows are charged with supporting the organization’s initiatives and overall ...
(Date:6/23/2020)... ... June 23, 2020 , ... First Aid Africa, ... a UK supplier and manufacturer of innovative portable renewable energy equipment, have announced ... fight against the COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD ...
Breaking Biology News(10 mins):